klhl40b Antibody

What is KLHL40 and why is it a significant research target?

KLHL40 (also known as Kelch-like protein 40, KBTBD5, or Sarcosynapsin) functions as a substrate-specific adapter within the BCR (BTB-CUL3-RBX1) E3 ubiquitin ligase complex that serves as a key regulator of skeletal muscle development. Unlike typical BBK family proteins that promote substrate degradation, KLHL40 uniquely stabilizes proteins like nebulin (NEB) and leiomodin 3 (LMOD3) by preventing their ubiquitination and subsequent degradation . This protein is particularly significant because mutations in KLHL40 are a frequent cause of severe autosomal-recessive nemaline myopathy, making it an important target for studying muscle development and disease mechanisms .

What types of KLHL40 antibodies are currently available for research?

Current commercially available KLHL40 antibodies are predominantly rabbit polyclonal antibodies. These include:

• Rabbit polyclonal anti-KLHL40 antibody targeting human KLHL40 (Atlas Antibodies)

• Rabbit polyclonal anti-KLHL40 antibody (400-450 aa) suitable for Western Blot applications (St John's Labs)

• Affinity-isolated rabbit polyclonal antibodies from Sigma-Aldrich (HPA024463)

Most of these antibodies have been validated for applications including immunohistochemistry (IHC), Western blot (WB), and immunocytochemistry/immunofluorescence (ICC-IF), with specificity for human and, in some cases, mouse KLHL40 .

How do zebrafish klhl40a and klhl40b compare to human KLHL40?

Zebrafish possess two KLHL40 orthologs, klhl40a and klhl40b, as identified through in situ hybridization studies. Research has demonstrated that these orthologs can be studied using morpholino-mediated knockdown, with antisense translation-blocking morpholinos specifically designed for each variant . While the search results don't provide direct sequence homology comparisons, the conservation of function between human KLHL40 and zebrafish orthologs makes zebrafish a valuable model organism for studying KLHL40-related muscle development and pathology. The functional conservation is supported by phenotypic similarities observed in morpholino knockdown experiments compared to human pathologies .

What validation methods should be employed to confirm KLHL40 antibody specificity?

Robust validation of KLHL40 antibodies should employ multiple complementary approaches:

• Orthogonal validation: Correlation between antibody staining patterns and RNA-seq data to confirm expression patterns match transcript levels (enhanced validation methodology used by Prestige Antibodies)

• Genetic models: Testing antibody reactivity in tissue from KLHL40 knockout models - knockout mouse models (Klhl40-/-) provide excellent negative controls for antibody specificity testing

• Multiple application testing: Validating across multiple techniques (IHC, WB, ICC-IF) to ensure consistent detection patterns

• Immunoprecipitation coupled with mass spectrometry: This approach was used in research settings to validate the binding partners of KLHL40, and can indirectly support antibody specificity

For zebrafish klhl40b studies specifically, antibody validation should include morpholino-injected embryos as negative controls, as demonstrated in previous research .

What are the optimal antibody dilutions for different experimental applications?

Based on the provided technical information, recommended antibody dilutions vary by application:

Optimal dilutions should be determined experimentally for each specific application and tissue type, using appropriate positive and negative controls. For zebrafish studies, dilution optimization would be particularly important due to potential cross-reactivity differences between human and zebrafish orthologs.

How can KLHL40 antibodies be used to study protein localization in muscle tissue?

KLHL40 exhibits specific subcellular localization that can be detected using immunofluorescence techniques:

Methodology for muscle tissue localization studies:

• Sample preparation: Fresh or frozen muscle samples should be sectioned (typically 5-10 μm thick) and fixed appropriately (4% paraformaldehyde is commonly used)

• Antigen retrieval: This may be necessary for formalin-fixed samples and should be optimized for KLHL40 detection

• Blocking and antibody incubation: Use KLHL40 antibodies at recommended dilutions (1:50-1:200 for immunohistochemistry)

• Co-localization markers: Combine with sarcomeric markers to identify specific bands

  • A-band markers (e.g., myosin)

  • I-band markers (e.g., actin)

• Analysis techniques: Confocal microscopy can precisely locate KLHL40 within the sarcomere structure

Research has demonstrated that KLHL40 localizes to both the I-band and A-band regions of the sarcomere. Previous conflicting reports were resolved using KLHL40-EGFP fusion proteins combined with second harmonic generation microscopy in relaxed myofibers, which clearly showed I-band localization .

What protocol modifications are needed when using KLHL40 antibodies for zebrafish studies?

When adapting protocols for zebrafish studies:

• Developmental stage selection: For studying klhl40a and klhl40b in zebrafish, embryonic and larval stages are recommended based on in situ hybridization patterns

• Fixation optimization: Paraformaldehyde fixation (typically 4%) for 2-4 hours at room temperature or overnight at 4°C is standard for zebrafish embryos

• Permeabilization: Additional permeabilization steps may be required due to the presence of developing scales and skin barriers

• Antibody cross-reactivity testing: Validate human KLHL40 antibodies against zebrafish klhl40a and klhl40b using morpholino knockdown controls to confirm specificity

• Whole-mount vs. section approach: Both approaches can be used depending on the developmental stage and specific research question

For functional studies, combine antibody staining with morpholino knockdown experiments targeting either klhl40a or klhl40b to establish ortholog-specific functions .

How can non-specific binding be reduced when using KLHL40 antibodies?

Non-specific binding is a common challenge with polyclonal antibodies. To minimize this issue:

• Blocking optimization: Extend blocking time (1-2 hours at room temperature) and test different blocking agents:

  • 5-10% normal serum from the same species as the secondary antibody

  • 3-5% BSA in PBS or TBS

  • Commercial blocking solutions specifically designed for muscle tissue

• Antibody dilution adjustment: Test a dilution series to find the optimal concentration that maximizes specific signal while minimizing background

• Washing stringency: Increase the number and duration of washes with PBS-T or TBS-T (0.1-0.3% Tween-20)

• Antigen retrieval optimization: Different antigen retrieval methods can affect epitope accessibility and non-specific binding

• Pre-absorption controls: When possible, pre-absorb the antibody with the immunizing peptide to confirm binding specificity

These approaches should be systematically tested and documented to establish optimal conditions for each experimental system.

What are the recommended storage conditions to maintain KLHL40 antibody integrity?

To preserve antibody function and prevent degradation:

• Storage temperature: Store at -20°C for long-term storage, as recommended by manufacturers

• Formulation: Commercial antibodies are typically supplied in a buffered solution containing stabilizers:

  • PBS with 50% glycerol

  • 0.5% BSA

  • 0.02% sodium azide

• Aliquoting: Upon receipt, divide the antibody into single-use aliquots to avoid repeated freeze-thaw cycles

• Freeze-thaw cycles: Minimize freeze-thaw cycles, as they can degrade antibody quality

• Working dilutions: Prepare fresh working dilutions on the day of use rather than storing diluted antibody

Proper storage can extend antibody shelf-life up to one year from the date of receipt as indicated by manufacturers .

How can KLHL40 antibodies be employed to study protein-protein interactions with its binding partners?

KLHL40 functions through interactions with several key binding partners. To study these interactions:

• Co-immunoprecipitation (Co-IP):

  • Use anti-KLHL40 antibodies to pull down KLHL40 complexes from muscle tissue or cell lysates

  • Identify binding partners by Western blot (targeted approach) or mass spectrometry (unbiased approach)

  • This approach has successfully identified NEB and LMOD3 as KLHL40 binding partners

• Proximity ligation assay (PLA):

  • Combine KLHL40 antibodies with antibodies against suspected binding partners

  • This can visualize interactions in situ with subcellular resolution

• FRET/BRET analysis:

  • Express tagged versions of KLHL40 and binding partners

  • Combine with antibody staining to confirm localization of interacting complexes

Research has demonstrated that KLHL40 interacts with NEB and LMOD3, functioning differently from typical BBK proteins by promoting stability rather than degradation of these partners .

What experimental approaches can be used to study KLHL40's role in muscle development and disease models?

To investigate KLHL40's functional role in muscle development and disease:

• Comparative analysis of wildtype and KLHL40-deficient tissues:

  • Use antibodies to quantify protein levels of KLHL40 targets (NEB and LMOD3) in wildtype versus knockout/patient tissues

  • Research has shown that NEB decreases by approximately 50% and LMOD3 is nearly eliminated in Klhl40-/- mouse muscle

• Rescue experiments in model systems:

  • Combine KLHL40 antibody staining with functional rescue experiments to assess protein level restoration

  • Monitor changes in binding partner stability following KLHL40 reintroduction

• Domain-specific function analysis:

  • Use antibodies to detect mutant versions of KLHL40 with specific domain deletions

  • Research shows the KR domain is essential for stabilizing both LMOD3 and NEB, while BTB and BACK domains are only essential for NEB stabilization

• Patient-derived sample analysis:

  • Use KLHL40 antibodies to assess protein expression in patient muscle biopsies

  • This approach has confirmed reduced NEB and LMOD3 levels in KLHL40-deficient patients

These advanced applications provide deeper insights into the mechanisms of KLHL40-related pathologies and potential therapeutic strategies.

How do antibody detection methods for zebrafish klhl40b compare with those for human KLHL40?

When conducting comparative studies between human and zebrafish systems:

• Cross-reactivity assessment: While some antibodies against human KLHL40 may cross-react with zebrafish orthologs, this should be experimentally validated through:

  • Western blot analysis of zebrafish tissue lysates

  • Immunohistochemistry with appropriate morpholino controls

  • Comparative immunoprecipitation studies

• Expression pattern comparisons: Research has utilized in situ hybridization with digoxigenin probes for klhl40a (1,340 bp) and klhl40b (694 bp) to map expression patterns in zebrafish, which can guide antibody application in specific tissues

• Developmental timing: When comparing human and zebrafish studies, consider the accelerated development timeline of zebrafish and adjust experimental endpoints accordingly

• Alternative detection methods: For zebrafish studies where direct antibody detection may be challenging, consider tagged expression constructs combined with antibody detection of the tag

This comparative approach can provide evolutionary insights into KLHL40 function while leveraging the experimental advantages of each model system.